We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Revvity Gears Up to Post Q3 Earnings: What's in Store for the Stock?
Read MoreHide Full Article
Key Takeaways
Revvity is set to report Q3 earnings on Nov. 3, with EPS expected to rise 9.3% on 0.3% revenue growth.
Strong HCS demand, recovering pharma spending and a Signals software rebound may boost Life Sciences.
Diagnostics strength and efficiency gains may aid RVTY, while weak academic spending and TB pressures.
Revvity, Inc. (RVTY - Free Report) is slated to report third-quarter 2026 results on Nov. 3, before market open. The company's performance is likely to reflect continued strength in Diagnostics and improving momentum in Life Sciences, supported by recovering pharma and biotech spending, robust demand for high-content screening (HCS) instruments and a return to double-digit growth in Signals software. However, persistent weakness in academic and government spending and continued latent TB-related pressures could weigh on performance.
In the last reported quarter, the company delivered an earnings surprise of 14.6%. RVTY’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.6%.
Year to date, RVTY’s shares have rallied 71.3%, outperforming the industry’s growth of 9.9% and the S&P Index’s rise of 12.4%.
Image Source: Zacks Investment Research
Q3 Estimates
The Zacks Consensus Estimate for third-quarter revenues is pegged at $700.9 million, indicating growth of 0.3% from the prior-year quarter’s level. The consensus mark for earnings is pinned at $1.29 per share, indicating an improvement of 9.3% year over year.
Factors Likely to Drive Revvity's Q3 Performance
Revvity's third-quarter results are expected to have benefited from resilience in its core Life Sciences and Diagnostics businesses, improving demand across its pharma and biotech customer base, which has shown signs of recovery since early 2026.
The Life Sciences segment may have gained momentum from stronger instrument shipments and improving software growth. HCS instruments are likely to have seen robust demand, supported by a strong backlog. Management expects instrument revenues to grow at a mid-single-digit rate in the third quarter. Reagent sales are also likely to have benefited from the fulfillment of larger orders deferred from the second quarter, supporting the upper end of low-single-digit growth.
Signals software is likely to have returned to high-teens organic growth in the third quarter, following a 20% decline in the second quarter due to difficult comparisons and contract timing. Advanced Persistent Virtual revenue and annual recurring revenue momentum are likely to have provided additional support. Recent AI-focused launches, including Signals AI, Xynthetica and the Anthropic connector, are likely to have strengthened customer engagement, although their revenue contribution may have remained relatively modest.
The Diagnostics segment is likely to have remained a key growth contributor, supported by sustained strength in reproductive health and immunodiagnostics. Newborn screening demand, broader portfolio adoption and geographic expansion may have supported reproductive health, although growth is likely to have moderated to low-single digits in the second half. Immunodiagnostics is likely to have benefited from healthy demand for rare autoimmune testing, particularly in the United States, while latent TB-related pressures may have remained a headwind.
Revvity's operational efficiency initiatives are expected to support profitability, with management anticipating benefits beginning in the third quarter. The company expects approximately 29% adjusted operating margins, alongside organic growth of 4-6% and revenues of $685-$700 million. However, softness in academic and government spending and macroeconomic uncertainty may have limited improvement.
Our proven model predicts an earnings beat for Revvity this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat, which is exactly the case here.
Revvity's Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is +1.03% for RVTY. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank of Revvity: The company carries a Zacks Rank #2 at present.
Other Stocks Worth a Look
Here are some other medical product stocks worth considering, as these too have the right combination of elements to post an earnings beat this reporting cycle.
PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.4%. The Zacks Consensus Estimate for the company’s first-quarter EPS indicates an increase of 8.2% from the year-ago quarter’s figure.
IDEXX Laboratories (IDXX - Free Report) currently has an Earnings ESP of +0.59% and a Zacks Rank #2. The company is slated to release third-quarter 2026 results on Nov. 2.
IDXX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 5.7%. The Zacks Consensus Estimate for the company’s third-quarter EPS implies an increase of 9.1% from the year-ago quarter’s figure.
Becton, Dickinson and Company (BDX - Free Report) , or BD, currently has an Earnings ESP of +0.21% and a Zacks Rank #2. The company is scheduled to release fourth-quarter fiscal 2026 results on Nov. 5.
BD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.9%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS calls for a rise of 2.5% from the year-ago quarter’s figure.
View the Zacks #1 Rank List
Image: Bigstock
Revvity Gears Up to Post Q3 Earnings: What's in Store for the Stock?
Key Takeaways
Revvity, Inc. (RVTY - Free Report) is slated to report third-quarter 2026 results on Nov. 3, before market open. The company's performance is likely to reflect continued strength in Diagnostics and improving momentum in Life Sciences, supported by recovering pharma and biotech spending, robust demand for high-content screening (HCS) instruments and a return to double-digit growth in Signals software. However, persistent weakness in academic and government spending and continued latent TB-related pressures could weigh on performance.
In the last reported quarter, the company delivered an earnings surprise of 14.6%. RVTY’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.6%.
Year to date, RVTY’s shares have rallied 71.3%, outperforming the industry’s growth of 9.9% and the S&P Index’s rise of 12.4%.
Image Source: Zacks Investment Research
Q3 Estimates
The Zacks Consensus Estimate for third-quarter revenues is pegged at $700.9 million, indicating growth of 0.3% from the prior-year quarter’s level. The consensus mark for earnings is pinned at $1.29 per share, indicating an improvement of 9.3% year over year.
Factors Likely to Drive Revvity's Q3 Performance
Revvity's third-quarter results are expected to have benefited from resilience in its core Life Sciences and Diagnostics businesses, improving demand across its pharma and biotech customer base, which has shown signs of recovery since early 2026.
The Life Sciences segment may have gained momentum from stronger instrument shipments and improving software growth. HCS instruments are likely to have seen robust demand, supported by a strong backlog. Management expects instrument revenues to grow at a mid-single-digit rate in the third quarter. Reagent sales are also likely to have benefited from the fulfillment of larger orders deferred from the second quarter, supporting the upper end of low-single-digit growth.
Signals software is likely to have returned to high-teens organic growth in the third quarter, following a 20% decline in the second quarter due to difficult comparisons and contract timing. Advanced Persistent Virtual revenue and annual recurring revenue momentum are likely to have provided additional support. Recent AI-focused launches, including Signals AI, Xynthetica and the Anthropic connector, are likely to have strengthened customer engagement, although their revenue contribution may have remained relatively modest.
The Diagnostics segment is likely to have remained a key growth contributor, supported by sustained strength in reproductive health and immunodiagnostics. Newborn screening demand, broader portfolio adoption and geographic expansion may have supported reproductive health, although growth is likely to have moderated to low-single digits in the second half. Immunodiagnostics is likely to have benefited from healthy demand for rare autoimmune testing, particularly in the United States, while latent TB-related pressures may have remained a headwind.
Revvity's operational efficiency initiatives are expected to support profitability, with management anticipating benefits beginning in the third quarter. The company expects approximately 29% adjusted operating margins, alongside organic growth of 4-6% and revenues of $685-$700 million. However, softness in academic and government spending and macroeconomic uncertainty may have limited improvement.
Revvity Inc. Price and EPS Surprise
Revvity Inc. price-eps-surprise | Revvity Inc. Quote
What the Zacks Model Unveils for RVTY
Our proven model predicts an earnings beat for Revvity this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat, which is exactly the case here.
Revvity's Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is +1.03% for RVTY. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank of Revvity: The company carries a Zacks Rank #2 at present.
Other Stocks Worth a Look
Here are some other medical product stocks worth considering, as these too have the right combination of elements to post an earnings beat this reporting cycle.
Phibro Animal Health (PAHC - Free Report) has an Earnings ESP of +2.10% and carries a Zacks Rank #2 at present. The company is set to release first-quarter fiscal 2027 results on Nov. 5. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.4%. The Zacks Consensus Estimate for the company’s first-quarter EPS indicates an increase of 8.2% from the year-ago quarter’s figure.
IDEXX Laboratories (IDXX - Free Report) currently has an Earnings ESP of +0.59% and a Zacks Rank #2. The company is slated to release third-quarter 2026 results on Nov. 2.
IDXX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 5.7%. The Zacks Consensus Estimate for the company’s third-quarter EPS implies an increase of 9.1% from the year-ago quarter’s figure.
Becton, Dickinson and Company (BDX - Free Report) , or BD, currently has an Earnings ESP of +0.21% and a Zacks Rank #2. The company is scheduled to release fourth-quarter fiscal 2026 results on Nov. 5.
BD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.9%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS calls for a rise of 2.5% from the year-ago quarter’s figure.